EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore

Cheng Ean Chee, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Jian Yi Choy, Meibo Hu, Amrita Viswambaram, Han Chong Toh

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2024.2319607 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Cheng Ean Chee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore. Hauptthemen laut MEDLINE: Bevacizumab, Sorafenib, Cost-Benefit Analysis, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Roche Singapore Pte Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aims to explore the cost-effectiveness of atezolizumab plus bevacizumab against sorafenib for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) in Singapore. METHODS: A partitioned survival model was developed from a healthcare system perspective, with a 10-year lifetime horizon. Clinical inputs and utilities were obtained from the IMbrave150 trial. Healthcare resource use costs were obtained from published local sources; drug costs reflected the most recent public hospital selling prices. Outcomes included life years, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses were performed to assess the model's robustness. RESULTS: Atezolizumab plus bevacizumab offered an additional 1.42 life years and 1.09 QALYs, with an additional cost of S$111,847; the ICER was S$102,988/QALY. The World Health Organization considers interventions with ICERs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabSorafenibCost-Benefit AnalysisLiver NeoplasmsCarcinoma, HepatocellularQuality-Adjusted Life YearsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansSingaporeDrug CostsCost-Effectiveness Analysis

Stichwörter der Autor:innen

Atezolizumabbevacizumabcost-effectivenesshepatocellular carcinomaprogrammed death ligand-1sorafenib

Substanzen

BevacizumabSorafenibatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, Singapore, Singapore.
  • Medical, Roche Singapore Pte Ltd, Singapore, Singapore.
  • Market Access, Roche Singapore Pte Ltd, Singapore, Singapore.
  • Market Access and Health Economics, Costello Medical Singapore Pte Ltd, Singapore, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Förderung

  • Roche Singapore Pte Ltd

Zitieren

APA

Chee, C. E., Khara, J. S., Cheong, J., Fong, J., Sivanesan, S., Choy, J. Y., Hu, M., Viswambaram, A., & Toh, H. C. (2024). Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2319607

Vancouver

Chee CE, Khara JS, Cheong J, Fong J, Sivanesan S, Choy JY, et al. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2319607

BibTeX
@article{Chee2024,
  author = {Chee, Cheng Ean and Khara, Jasmeet Singh and Cheong, John and Fong, Jek and Sivanesan, Sivabalan and Choy, Jian Yi and Hu, Meibo and Viswambaram, Amrita and Toh, Han Chong},
  title = {Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2024.2319607}
}
Kostenlos starten →